Dr. John Cush RheumNow
2 years 7 months ago
Methotrexate Nodulosis
How good (or not) are rheumatologists and what to do about MTX nodulosis?
https://t.co/Ot9UfpH68N https://t.co/JQ2AtuE7NV
Dr. John Cush RheumNow
2 years 7 months ago
11-yr French study of #RA Pregnancies: more adverse Preg outcomes in RA, esp w/ active Dz. 11.8K RA vs 10.4 million non-RA Pregs. 75% live births in RA. RA had more preterm(aOR 1.84), low birth wt (1.65), C-Sect (1.46), hospz (1.30), & prematurity (2.02)https://t.co/v9CmiPkIBG https://t.co/S0siiuG0oZ
Dr. John Cush RheumNow
2 years 7 months ago
Mexico survey of 250 RA pts -- 92% used complementary (CAM) therapies - mostly: herbals (65%), homeopathy (64%), cannabis derivatives (51%). Poor DMARD adherence assoc w/ age (p=0.019), comorbidities (p=0.047), CAM use (p = 0.042) (OR 2.84) https://t.co/EGxyIVCMnk https://t.co/jjF5cH53we
Dr. John Cush RheumNow
2 years 7 months ago
FDA Safety Warning: denosumab now has a Boxed Warning for risk of severe hypocalcemia in CKD pts taking Prolia (usually seen 2-10 wks post injx). Pts may or may not be symptomatic. CKD pts should have Ca and Creatinine monitored. https://t.co/tGiG35cOnv https://t.co/ITOZneGKtb
Dr. John Cush RheumNow
2 years 7 months ago
Rheumatologists and the Early Diagnosis of Spondyloarthritis
SPACE study of adults referred to rheumatology with less than 2 years of chronic back pain (CBP), shows that only one-third can be reliably diagnosed with axial spondyloarthritis (axSpA).
https://t.co/EwrrunyZs7. https://t.co/T0OqlsuU2P
Dr. John Cush RheumNow
2 years 7 months ago
Rheumatologists: What is your preferred MOA/Drug in treating Psoriatic Arthritis?
The American College of Rheumatology (ACR), on behalf of over 9,100 rheumatologists and rheumatology professional team members, applauds the Centers for Medicare and Medicaid Services (CMS) for finalizing its Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations rule recently.
Dr. John Cush RheumNow
2 years 7 months ago
Rituximab Efficacy in MAINRITSAN Long-Term Studies
https://t.co/z16uMDihV4 https://t.co/BaWFcwDbYL
Dr. John Cush RheumNow
2 years 7 months ago
Sodium Channels, Carbemazepine and Osteoarthritis Progression
A study published in Nature suggests that therapies affecting sodium channels could be employed to treat osteoarthritis.
https://t.co/hmzKsgb3gA https://t.co/WVgk8nD4ne
Dr. John Cush RheumNow
2 years 7 months ago
You can still attend RheumNow Live!
Below is a preview of one of our "STEP" talks - by Mike Putman, MD, who brings his vast knowledge to the forefront, shedding light on Myths & Mistakes on ANCA-Associated Vasculitis.
https://t.co/LzcVytLDij
Register: https://t.co/NWXKNhQzc5 https://t.co/ogAfTtH5Nk
On 1-19-2024, the Food and Drug Administration (FDA) issued a Drug Safety Communication about the risk of severe hypocalcemia in chronic kidney disease (CKD) patients taking denosumab for osteoporosis, with an accentuated risk in older women who are dialysis-dependent.
This report is an update to their November 2022 investigation, the results of a related study being recently reported in JAMA.
Dr. John Cush RheumNow
2 years 7 months ago
New download available!
Seasonal Flu Vaccination in RA Patients
https://t.co/tNwgUVoG7Z https://t.co/P1UqPU57WU
Dr. John Cush RheumNow
2 years 7 months ago
IL-17 pathway as a target in giant cell arteritis - full read review of pathogenic role of IL-17 and Th17 cells, in #GCA; backed up by the phase II proof-of-principle TiTAIN study showing potential efficacy of secukinumab in GCA pts https://t.co/MThzw2joGO https://t.co/PmrJjf9C3a
Dr. John Cush RheumNow
2 years 7 months ago
2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update
EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA).
https://t.co/OjmdAnRWtl https://t.co/gfWYopEgtt
Dr. John Cush RheumNow
2 years 7 months ago
Japanese retrospective study compared RA pts on JAK inhib vs bDMARDs (n=62 ea) having orthopedic surgery; JAKi- pts had more postoperative flares (29% v 12%, P=.01), esp if JAKi held >11d (p.04). No diff in other postop complications https://t.co/NVY1Oajdve https://t.co/fwc9KWYZ9l

